Oral management with polaprezinc solution reduces adverse events in haematopoietic stem cell transplantation patients
| Autor: | Honoka Arai, Maki Tsubura-Okubo, Ryouta Kamimura, H. Ishihama, K. Mitani, Yasuo Haruyama, Yuske Komiyama, Yuta Sawatani, Daisuke Uchida, Hitoshi Kawamata, Gen Kobashi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Graft vs Host Disease Gastroenterology Sepsis 03 medical and health sciences 0302 clinical medicine Internal medicine Mucositis Organometallic Compounds Medicine Humans Transplantation Homologous Adverse effect business.industry Septic shock Carnosine Hematopoietic Stem Cell Transplantation 030206 dentistry medicine.disease Dysgeusia Transplantation surgical procedures operative Otorhinolaryngology Zinc Compounds 030220 oncology & carcinogenesis Concomitant Surgery Oral Surgery medicine.symptom business Febrile neutropenia |
| Zdroj: | International journal of oral and maxillofacial surgery. 50(7) |
| ISSN: | 1399-0020 |
| Popis: | The aim of this study was to analyse the effects of gargling with and then swallowing PPAA (polaprezinc in polyacrylic acid solution), in addition to regular oral management, on patients with a haematopoietic neoplasm scheduled for haematopoietic stem cell transplantation (HSCT). A total of 120 patients scheduled for HSCT during the years 2006-2016 were recruited. Patient background, oral adverse events, the incidence and severity of systemic adverse events (sepsis/septic shock, acute graft-versus-host disease (GVHD) after transplantation), and outcomes (survival/death) were compared between groups treated with and without PPAA. The severities of oral adverse events (oral mucositis, oral pain, and dysgeusia) were significantly lower in patients treated with PPAA. There was no significant difference in the incidence of febrile neutropenia (P=0.622) or sepsis/septic shock (P=0.665) as systemic adverse events. The severity of allograft-induced acute graft-versus-host disease (GVHD) was significantly lower in the PPAA group (P=0.011). There was no significant difference in outcome between the two groups (P=0.285). Within the limitations of the study design, it may be concluded that oral management with PPAA reduces adverse events in HSCT. Oral management with concomitant use of PPAA decreased oral adverse events and reduced the systemic complication of GVHD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect